Success Metrics

Completion Rate
0%(0/2)
Active Trials
7(64%)
Terminated
2(18%)

Phase Distribution

Ph early_phase_1
1
9%
Ph phase_3
1
9%
Ph phase_1
3
27%
Ph phase_2
5
45%

Phase Distribution

4

Early Stage

5

Mid Stage

1

Late Stage

Phase Distribution10 total trials
Early Phase 1First-in-human
1(10.0%)
Phase 1Safety & dosage
3(30.0%)
Phase 2Efficacy & side effects
5(50.0%)
Phase 3Large-scale testing
1(10.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

7

trials recruiting

Total Trials

11

all time

Status Distribution
Active(8)
Terminated(2)
Other(1)

Detailed Status

Recruiting7
Terminated2
unknown1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
7
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (10.0%)
Phase 13 (30.0%)
Phase 25 (50.0%)
Phase 31 (10.0%)

Trials by Status

unknown19%
not_yet_recruiting19%
recruiting764%
terminated218%

Recent Activity

7 active trials
Showing 5 of 11
recruitingphase_2

A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

NCT05828069
recruitingphase_1

A Study to Assess a Medicine Called Tovorafenib in Japanese Children and Young Adults With Brain Tumours

NCT07441707
recruitingphase_1

Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia

NCT06965114
recruitingphase_2

Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults

NCT05465174
not_yet_recruitingphase_2

Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)

NCT07206849
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT05828069Phase 2

A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

Recruiting
NCT07441707Phase 1

A Study to Assess a Medicine Called Tovorafenib in Japanese Children and Young Adults With Brain Tumours

Recruiting
NCT06965114Phase 1

Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia

Recruiting
NCT05465174Phase 2

Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults

Recruiting
NCT07206849Phase 2

Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)

Not Yet Recruiting
NCT05566795Phase 3

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

Recruiting
NCT04985604Phase 2

Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors

Terminated
NCT07121829Phase 1

Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors

Terminated
NCT06381570Early Phase 1

Pilot Study of Vinblastine and Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade Gliomas

Recruiting
NCT04775485Phase 2

A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors

Recruiting
NCT05760586

Expanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade Glioma

Unknown

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11